The role of amino acids in some forms of mito
On May 9, 2026, International Mito Patients was represented at the Cognate Amino Acid for tRNA Synthetase Disorders Consortium meeting […]
mitochondrial diseases
UCB calls all artists in the mitochondrial disease community
This year UCB is collaborating with the global Mitochondrial disease community to collect works of art (painting, poetry, photography, sculpture,
Effect of a Mitochondrial Genetic Variant on Sevoflurane Hypersensitivity
Five years ago, a research project began that is now influencing anesthetic practice worldwide. It all started when Dr. Yaremy
First Patient Dosed in Phase 3 KHENERFIN Study of Sonlicromanol for m.3243A>G Primary Mitochondrial Disease
First Patient Dosed in Phase 3 KHENERFIN Study of Sonlicromanol for m.3243A>G Primary Mitochondrial Disease Khondrion has announced a major
IMP Welcomes New Members from China, Spain and US
We are delighted to announce that three additional mitochondrial organisations have joined IMP, further strengthening our global network and amplifying
IMP welcomes European Commission approval of KYGEVVI® for TK2d
European Commission approves KYGEVVI® for TK2d IMP warmly welcomes the decision by the European Commission to approve KYGEVVI® (doxecitine and doxribtimine) as
New MELAS Consensus: A Critical Resource for Doctors and Patients Worldwide
New MELAS Consensus: A Critical Resource for Doctors and Patients Worldwide In November 2025, leading international experts gathered in Pisa,
Inside the Mito Town Hall: Insights That Matter
Inside the Mito Town Hall: Insights That Matter The Mito Town Hall meetings have become an important annual touchpoint for
Setback for LHON Treatment in the US: IMP Supports Urgent Patient Need
Setback for LHON Treatment in the US: IMP Supports Urgent Patient Need International Mito Patients (IMP), the global federation representing patient
EMA grants positive CHMP opinion for KYGEVVI® for Treatment of TK2d
EMA grants positive CHMP opinion for Kygevvi® for Treatment of TK2d International Mito Patients (IMP) and the global mitochondrial disease community